Co-occurrence of mutations
| . | PV JAK2V617F . | ET JAK2V617F . | ET CALRmut . | ET MPLm . | PMF JAK2V617F . | PMF CALRmut . | PMF MPLm . |
|---|---|---|---|---|---|---|---|
| % (No. of patients) . | |||||||
| TET2 | 8.33 (4) | 5.26 (3) | 0 (0) | 0 (0) | 28.95 (11) | 2.63 (1) | 2.63 (1) |
| DNMT3A | 6.25 (3) | 7.02 (4) | 0 (0) | 3.51 (2) | 7.89 (3) | 0 (0) | 0 (0) |
| ASXL1 | 0 (0) | 3.51 (2) | 0 (0) | 1.75 (1) | 15.79 (6) | 7.89 (3) | 0 (0) |
| IDH1/IDH2 | 2.08 (1) | 1.75 (1) | 0 (0) | 0 (0) | 2.63 (1) | 0 (0) | 0 (0) |
| EZH2 | 2.08 (1) | 0 (0) | 1.75 (1) | 0 (0) | 2.63 (1) | 2.63 (1) | 0 (0) |
| SF3B1 | 4.17 (2) | 0 (0) | 0 (0) | 0 (0) | 2.63 (1) | 0 (0) | 0 (0) |
| U2AF1 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 7.89 (3) | 0 (0) | 0 (0) |
| . | PV JAK2V617F . | ET JAK2V617F . | ET CALRmut . | ET MPLm . | PMF JAK2V617F . | PMF CALRmut . | PMF MPLm . |
|---|---|---|---|---|---|---|---|
| % (No. of patients) . | |||||||
| TET2 | 8.33 (4) | 5.26 (3) | 0 (0) | 0 (0) | 28.95 (11) | 2.63 (1) | 2.63 (1) |
| DNMT3A | 6.25 (3) | 7.02 (4) | 0 (0) | 3.51 (2) | 7.89 (3) | 0 (0) | 0 (0) |
| ASXL1 | 0 (0) | 3.51 (2) | 0 (0) | 1.75 (1) | 15.79 (6) | 7.89 (3) | 0 (0) |
| IDH1/IDH2 | 2.08 (1) | 1.75 (1) | 0 (0) | 0 (0) | 2.63 (1) | 0 (0) | 0 (0) |
| EZH2 | 2.08 (1) | 0 (0) | 1.75 (1) | 0 (0) | 2.63 (1) | 2.63 (1) | 0 (0) |
| SF3B1 | 4.17 (2) | 0 (0) | 0 (0) | 0 (0) | 2.63 (1) | 0 (0) | 0 (0) |
| U2AF1 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 7.89 (3) | 0 (0) | 0 (0) |
Results are extracted from Nangalia et al29 because it is one of the rare studies in which all types of MPNs are available. Overall, 143 patients: PV, 43; ET, 57; and PMF, 38. Percentages are expressed for each MPN, irrespective of the MPN drive mutation. Thus, percentages are calculated on a very low number of patients due to the heterogeneity of the disorder, explaining differences with other studies, more particularly for the mutations in splicing genes.